Raise money for WAMES at Christmas through Amazon Smile

You shop. Amazon gives, with a smile.  Choose WAMES!

 

AmazonSmile is the same Amazon you know. Same products, same prices, same service.

Shop at smile.amazon.co.uk and they will donate to your favourite charitable organisation, at no cost to you.

  • Go to https://smile.amazon.co.uk
  • Sign in to your account or register a new account
  • Name WAMES as the charity you wish to support
  • Now shop – Amazon will send money to WAMES
  • Or go directly to support WAMES

 

Choose WAMES now and help keep us on the campaign trail!

Posted in News | Tagged , | Comments Off on Raise money for WAMES at Christmas through Amazon Smile

Cardiac dimensions & function are not altered among females with the ME/CFS

Cardiac dimensions and function are not altered among females with the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, by  Per Ole Iversen, Thomas Gero von Lueder, Kristin Reimers Kardel and Katarina Lien in Healthcare 2020, 8(4), 406 [doi.org/10.3390/healthcare8040406]

 

Research abstract:

Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating condition associated with several negative health outcomes. A hallmark of ME/CFS is decreased exercise capacity and often profound exercise intolerance. The causes of ME/CFS and its related symptoms are unknown, but there are indications of a dysregulated metabolism with impaired glycolytic vs oxidative energy balance.

In line with this, we recently demonstrated abnormal lactate accumulation among ME/CFS patients compared with healthy controls after exercise testing. Here we examined if cardiac dimensions and function were altered in ME/CFS, as this could lead to increased lactate production.

Methods: We studied 16 female ME/CFS patients and 10 healthy controls with supine  and we assessed cardiac dimensions and function by conventional echocardiographic and Doppler analysis as well as novel tissue Doppler and strain variables.

Results: A detailed analyses of key variables of cardiac dimensions and cardiac function revealed no significant differences between the two study groups.

Conclusion: In this cohort of well-described ME/CFS patients, we found no significant differences in echocardiographic variables characterizing cardiac dimensions and function compared with healthy controls.

(This article belongs to the Special Issue ME/CFS – the Severely and Very Severely Affected)

Posted in News | Tagged , , , , , | Comments Off on Cardiac dimensions & function are not altered among females with the ME/CFS

Long covid & ME/CFS: doctors must assess, investigate & diagnose patients properly

BMJ: Long covid: doctors must assess and investigate patients properly, by Dr Nina Muirhead,  9 December 2020

 

Dr Nina Muirhead, a dermatology surgeon in Buckinghamshire & lecturer at Cardiff Medical School responds to an article in the British Medical Journal.

 

Dear Editor

I strongly echo this sentiment from my long COVID colleagues about assessing and investigating patients properly and would like to add that doctors must also diagnose patients properly. We should not treat long COVID as anxiety, nor confuse primary psychological sequalae of COVID with the multisystem disease ME/CFS.

COVID-19 can leave emboli, pulmonary fibrosis, organ damage and myocarditis in its wake. Many ‘long-haulers’ are struggling at home and still recording symptoms without a diagnosis or prognosis. Their acute COVID experience may have ranged from mild to severe, but they have not felt better after the expected twelve-day average. This heterogenous group are presenting with multiple symptoms: fatigue, headaches, ‘lung burn’, sore throats, chest pains, irritable bowel, night sweats, rashes, brain fog, muscle, bone and joint pains, changing sleep, palpitations, burning skin, dizziness, tingling, tinnitus, difficulty concentrating – the list goes on. Days have turned to weeks, and weeks have turned to months. Will months turn to years, or years to decades?

A subset of ‘chronic COVID-19’ patients do not have familiar organic pathology to explain their symptoms, they know their experience is not imagined, nor secondary to anxiety. Fit individuals walk or exercise, yet, on other days, struggle to climb the stairs or get out of bed.

Symptoms flare in the hours or days after trivial physical, emotional, or cognitive effort. Many are still functioning at a fraction of their pre-COVID normal. Others fluctuate between recovery and relapse.

Shockingly, some are facing difficulty being believed, or told their symptoms are secondary to anxiety or depression. The Royal College of GPs have produced a short module linking long COVID to anxiety and post-traumatic stress, but many long COVID patients would not be anxious if they felt well. There are calls for a new narrative. Are we on the verge of defining a new disease, or are many of these patients experiencing the reality of ME/CFS?

When the COVID-19 global viral pandemic hit, the online ME/CFS community went wild: “There will be an explosion of post-COVID patients with ME.” “How will the NHS deal with the impending ME tsunami?” ME/CFS is a common, complex, chronic, multisystem disease affecting tens of millions of patients worldwide. Many cases are triggered by a viral infection and up to a quarter of patients are bedbound or housebound. ME/CFS appears to be the neglected illness of the 21st Century, residing in a medical blind-spot. ME/CFS is widely misunderstood and should neither be a diagnosis of exclusion nor an exclusive diagnosis. Evidence shows patients suffer from inflammation, autonomic and metabolic dysregulation and altered mitochondrial function. Exertion results in an exacerbation of symptoms and exercise is not recommended as a treatment.

Identifying ME/CFS patients amongst, and alongside, those with ‘chronic COVID-19’ is vital. It is also crucial that we learn to differentiate between patients suffering from anxiety, depression and post-traumatic stress from those developing a complex multisystem disease, which as yet has no biomarker. I do not deny the interplay between body and mind, but depression and anxiety can be reduced with exercise whilst ME/CFS can be exacerbated. Unless we learn to recognise the difference, progress will not be made. The burden of illness should be recorded and epidemiological data collected to drive scientific and biomedical research. Some experienced ME/CFS clinicians are convinced that many long COVID patients are suffering from ME/CFS.

However not all long COVID patients fit the diagnostic criteria for ME/CFS and worse, there is widespread ignorance that ME/CFS is psychological, such that many who are anxious and depressed at this stage could be mislabeled as having ME/CFS.

Do long COVID and ME/CFS patients think they have the same disease?

There are reservations on both sides. Long COVID patients do not want their disease to be misjudged, underestimated, or ignored. Healthcare professionals with long COVID seem the most reticent that long COVID and ME/CFS are conflated. This is particularly the case for those who were taught the outdated biopsychosocial narrative for ME/CFS, they know exercise and psychotherapy are not the answer. ME/CFS patients think their lived experience of real, debilitating, chronic, complex disease could be a great source of support. After a diagnosis ME/CFS and long COVID patients all require appropriate support from their GP, employer, family and friends. They need regular review and may develop other comorbidities.

This debate has implications for guidelines, funding, government, policy and practice. Many healthcare professionals with long COVID have struggled to resume full time work. These reports are the tip of the iceberg, patients who ignore symptoms and push through may get worse. The peak of bedbound and housebound patients could hit at around 2-5 years, others may deteriorate over decades. The mean duration of ME/CFS in children and young people is five years but in adults as few as 5% are estimated to make a full recovery. Early advice to rest has been shown to reduce the future burden on work rehabilitation and medical retirement. ME/CFS is already estimated to cost the UK economy £3.3 billion per year, can we afford to add thousands of long COVID patients to the millions already missing?

When long COVID patients report that the harder they push to get better, the more their bodies fail them, we must listen and take note.

Fatigue, pain, sleep disturbance and brain fog are debilitating and have a major impact on quality of life. Exercise has the potential to exacerbate symptoms and may inhibit cellular energy delivery. NICE has wisely advised caution against using graded exercise therapy for post COVID patients. Objective assessments for orthostatic intolerance, neuroinflammation, altered cellular bioenergetics, grip strength and cardiopulmonary exercise testing (CPET) should be part of rehabilitation assessment. Repeat CPET may indicate if exercise is making patients better, or worse.

Long COVID and ME/CFS are complex and heterogeneous. Both need greater recognition and research. The worst outcome would be to ignore or dismiss both. There is a pressing need for better education so that we can take the right approach and avoid causing patients harm.

Competing interests: I have no financial conflict of interest. I have provided expert testimony to NICE on education, information and support for healthcare professionals on ME/CFS and am chair of the CFS/ME education working group (CMRC) I am a member of Forward ME, I am a doctor working for the NHS and a patient with ME/CFS.

Posted in News | Tagged , , , | Comments Off on Long covid & ME/CFS: doctors must assess, investigate & diagnose patients properly

ME/CFS symptoms – videos of patients’ experiences

Dialogues for ME/CFS videos – Symptoms

 

The latest videos in the ‘Dialogues for a neglected illness’ series gives patients’ accounts of a variety of key symptoms experienced in ME/CFS.

 

  1. Reduced Function – 20 mins

  2. How does the disease start? – 28 mins

  3. Post Exertional Malaise – 22 mins

  4. Cognitive Impairment – 18 mins

  5. Sleep – 12 mins

  6. Orthostatic intolerance – 12 mins

  7. Pain – 12 mins

  8. Hypersensitivity – 13 mins

 

Watch the films on the Dialogues for ME/CFS website

 

Posted in News | Tagged , , , | Comments Off on ME/CFS symptoms – videos of patients’ experiences

Christmas shop online with Easy Fundraising – raise funds for WAMES

Christmas shop online & fundraise at the same time!

 

Register with easyfundraising.org.uk in 3 easy steps and raise money to keep WAMES campaigning at no cost to yourself.

Every time you want to shop, go to easyfundraising.org.uk and select any of 4,300+ stores. Retailers include:

  • Amazon
  • high street stores like John Lewis, M&S, Argos,
  • Ebay
  • Grocery stores like Sainsbury, Tesco
  • Transport sites like Trainline, Virgin
  • Insurance companies
  • Mobile phone companies, and many more…

Ask friends and families, employers and colleagues to join easyfundraising and ‘choose WAMES’.

  1. Join          Head to  https://www.easyfundraising.org.uk/causes/wames/ and sign up for free.
  2. Shop       Every time you shop online, go to easyfundraising first, pick the retailer you want and start shopping.
  3. Raise       After you’ve checked out, that retailer will make a donation to us and it won’t cost you a penny extra!

Please help us when you’re shopping online at Christmas and in the sales – there are no catches or hidden charges and WAMES will be really grateful for your donations.

PS you can download an app for Android & iOS a ‘donation reminder’ for your PC

A BIG thank you to all who have already signed up. The money you have raised makes a big difference to WAMES.

Posted in News | Comments Off on Christmas shop online with Easy Fundraising – raise funds for WAMES

Impact of long-term cryopreservation on blood immune cell markers in ME/CFS: implications for biomarker discovery

Impact of long-term cryopreservation on blood immune cell markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: implications for biomarker discovery, by Elisabet Gómez-Mora,  Jorge Carrillo,  Víctor Urrea,  Josepa Rigau,  José Alegre,  Cecilia Cabrera,  Elisa Oltra,  Jesús Castro-Marrero and  Julià Blanco in Front. Immunol., 17 November 2020 [doi.org/10.3389/fimmu.2020.582330]

 

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex neuroimmune disorder characterized by numerous symptoms of unknown etiology. The ME/CFS immune markers reported so far have failed to generate a clinical consensus, perhaps partly due to the limitations of biospecimen biobank.

To address this issue, we performed a comparative analysis of the impact of long-term biobanking on previously identified immune markers and also explored additional potential immune markers linked to infection in ME/CFS. A correlation analysis of marker cryostability across immune cell subsets based on flow cytometry immunophenotyping of fresh blood and frozen PBMC samples collected from individuals with ME/CFS (n = 18) and matched healthy controls (n = 18) was performed.

The functionality of biobanked samples was assessed on the basis of cytokine production assay after stimulation of frozen PBMCs. T cell markers defining Treg subsets and the expression of surface glycoprotein CD56 in T cells and the frequency of the effector CD8 T cells, together with CD57 expression in NK cells, appeared unaltered by biobanking. By contrast, NK cell markers CD25 and CD69 were notably increased, and NKp46 expression markedly reduced, by long-term cryopreservation and thawing. Further exploration of Treg and NK cell subsets failed to identify significant differences between ME/CFS patients and healthy controls in terms of biobanked PBMCs.

Our findings show that some of the previously identified immune markers in T and NK cell subsets become unstable after cell biobanking, thus limiting their use in further immunophenotyping studies for ME/CFS. These data are potentially relevant for future multisite intervention studies and cooperative projects for biomarker discovery using ME/CFS biobanked samples. Further studies are needed to develop novel tools for the assessment of biomarker stability in cryopreserved immune cells from people with ME/CFS.

Posted in News | Tagged , , , , , , , , , , , , , , | Comments Off on Impact of long-term cryopreservation on blood immune cell markers in ME/CFS: implications for biomarker discovery

High prevalence of perineural cysts in patients with FM & CFS

High prevalence of perineural cysts in patients with fibromyalgia and Chronic Fatigue Syndrome, by Mieke Hulens, Frans Bruyninckx, Wim Dankaerts, Ricky Rasschaert, Peter De Mulder, Ingeborg Stalmans, Greet Vansant, Chris Bervoets in Pain Medicine, 1 Dec 2020 pnaa410 [doi.org/10.1093/pm/pnaa410]

 

Research abstract

Objective:
Pain in fibromyalgia (FM) and chronic fatigue syndrome (CFS) is assumed to originate from central sensitization. Perineural cysts or Tarlov cysts (TCs) are nerve root dilations resulting from pathologically increased cerebrospinal fluid pressure. These cysts initially affect sensory neurons and axons in dorsal root ganglia and produce sensory symptoms (pain and paresthesia). Symptomatic TC (STC) patients often complain about widespread pain and fatigue. Consequently, STC patients may initially be diagnosed with FM, CFS, or both. The objective of this study was to document the prevalence of TCs in patients diagnosed with FM or CFS.

Design:
A retrospective study.

Setting:
An outpatient clinic for musculoskeletal disorders.

Subjects:
Patients diagnosed with FM according to the 1990 American College of Rheumatology criteria or with CFS according to the 1994 Centers for Disease Control criteria were selected.

Methods:
Review of lumbar and sacral magnetic resonance imaging scans including TCs ≥5 mm in size.

Results:
In total, 197 patients with FM, CFS, or both underwent magnetic resonance imaging. Ninety-one percent were women. The mean age was 48.1 (±11.9) years. TCs were observed in 39% of patients, with a mean size of 11.8 (±5.2) mm. In males, the prevalence was 12%, vs. 42% in females.

Conclusions:
In patients diagnosed with FM or CFS, the prevalence of TCs was three times higher than that in the general population. This observation supports the hypothesis that STCs, FM, and CFS may share the same pathophysiological mechanism, i.e., moderately increased cerebrospinal fluid pressure, causing irritation of neurons and axons in dorsal root ganglia.

 

Read full article

Posted in News | Tagged , , , , , , , , , , , , , | Comments Off on High prevalence of perineural cysts in patients with FM & CFS

Role of mitochondria, oxidative stress & the response to antioxidants ME/CFS: a possible approach to SARS-CoV-2 ‘long-haulers’?

Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 ‘long-haulers’?, by , Warren Tate in Chronic Dis Transl Med. 2020 Nov 21 [doi: 10.1016/j.cdtm.2020.11.002]

 

Review article abstract:

A significant number of SARS-CoV-2 (COVID-19) pandemic patients have developed chronic symptoms lasting weeks or months which are very similar to those described for myalgic encephalomyelitis/chronic fatigue syndrome.

This paper reviews the current literature and understanding of the role that mitochondria, oxidative stress and antioxidants may play in the understanding of the pathophysiology and treatment of chronic fatigue. It describes what is known about the dysfunctional pathways which can develop in mitochondria and their relationship to chronic fatigue.

It also reviews what is known about oxidative stress and how this can be related to the pathophysiology of fatigue, as well as examining the potential for specific therapy directed at mitochondria for the treatment of chronic fatigue in the form of antioxidants. This review identifies areas which require urgent, further research in order to fully elucidate the clinical and therapeutic potential of these approaches.

Conclusion

Research into mitochondrial function of ME/CFS has been increasing in recent years and appears to hold potential for better understanding this enigmatic disease that may be increasing its prevalence as a result of the SARS-CoV-2 pandemic. So far, however, the results have proved somewhat contradictory. There are several reasons for this.

An accurate diagnosis for ME/CFS is difficult in the absence a molecular biomarker diagnostic test, individuals in the ME/CFS group are often heterogeneous and have differing disease severity.

There are multiple clinical case definitions that are being used for diagnosis. A vicious circle exists: without a biochemical diagnostic test it is difficult to be certain which patients have ME/CFS and not another fatigue illness with overlapping symptoms, but determining a valid test requires identifying an homogenous group of test subjects.

If ME/CFS is indeed a state of CoQ10 deficiency – particularly in high energy-demand organs like the brain – then an effective way of assessing CoQ10 is needed. This could then be a cellular biomarker that is monitored after oral supplementation in treatment of ME/CFS. Changes in mitochondrial function and markers of oxidative stress may be the biological component most impacted upon by CoQ10 supplementation, due to CoQ10’s vital role in the electron transport chain.

There is also clear need to establish whether MitoQ does indeed improve mitochondrial function and oxidative stress and lessens symptoms in both ME/CFS and chronic symptoms from SARS-CoV-19. There is a biologically plausible mechanism for expected improvement with MitoQ’s superior bioavailability to cells and to mitochondria within them, and by how it can restore oxidative balance and therefore improve mitochondrial function.

A respiratory index, like the BHI, also has the potential to predict and monitor pathophysiology in both ME/CFS and ‘long-haulers’ from SARS-CoV-2. Further research into ME/CFS and SARS-CoV-2, two perplexing and seriously debilitating diseases, is urgently required.

Posted in News | Tagged , , , , , , , , , , , | Comments Off on Role of mitochondria, oxidative stress & the response to antioxidants ME/CFS: a possible approach to SARS-CoV-2 ‘long-haulers’?

Systematic review of Primary Outcome Measurements for CFS/ME in randomized controlled trials

Systematic review of primary Outcome Measurements for Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME) in randomized controlled trials, by  Do-Young Kim, Jin-Seok Lee and Chang-Gue Son in J. Clin. Med. 2020, 9(11) 3463 [doi.org/10.3390/jcm9113463] (This article belongs to the Special Issue Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: Diagnosis and Treatment)

 

Research abstract:

Background:

Due to its unknown etiology, the objective diagnosis and therapeutics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) are still challenging.

Generally, the patient-reported outcome (PRO) is the major strategy driving treatment response because the patient is the most important judge of whether changes are meaningful.

Methods:

In order to determine the overall characteristics of the main outcome measurement applied in clinical trials for CFS/ME, we systematically surveyed the literature using two electronic databases, PubMed and the Cochrane Library, throughout June 2020. We analyzed randomized controlled trials (RCTs) for CFS/ME focusing especially on main measurements.

Results:

Fifty-two RCTs out of a total 540 searched were selected according to eligibility criteria. Thirty-one RCTs (59.6%) used single primary outcome and others adapted ≥2 kinds of measurements. In total, 15 PRO-derived tools were adapted (50 RCTs; 96.2%) along with two behavioral measurements for adolescents (4 RCTs; 7.7%). The 36-item Short Form Health Survey (SF-36; 16 RCTs), Checklist Individual Strength (CIS; 14 RCTs), and Chalder Fatigue Questionnaire (CFQ; 11 RCTs) were most frequently used as the main outcomes. Since the first RCT in 1996, Clinical Global Impression (CGI) and SF-36 have been dominantly used each in the first and following decade (26.1% and 28.6%, respectively), while both CIS and Multidimensional Fatigue Inventory (MFI) have been the preferred instruments (21.4% each) in recent years (2016 to 2020).

Conclusions:

This review comprehensively provides the choice pattern of the assessment tools for interventions in RCTs for CFS/ME. Our data would be helpful practically in the design of clinical studies for CFS/ME-related therapeutic development.

Posted in News | Tagged , , , , , , | Comments Off on Systematic review of Primary Outcome Measurements for CFS/ME in randomized controlled trials

Paradigm shift to disequilibrium in the genesis of orthostatic intolerance

Paradigme shift to disequilibrium in the genesis of orthostatic intolerance in patients with CFS, by K Miwa in European Heart Journal Vol 40, Supp 1, Oct 2019

 

Research abstract

Background
Chronic fatigue syndrome (CFS) characterized by severe disabling fatigue and prolonging post-exertional malaise. The dysfunction of the central nervous system associated with myalgic encephalomyelitis (ME) has been postulated as the main cause of CFS. Orthostatic intolerance (OI) causes a marked reduction in the activities of daily living and impairs the quality of life in patients with ME/CFS. OI has been surmised to be a cardiovascular symptom with cerebral hypo-perfusion and exaggerated sympathetic nervous activation.

Purpose
Postural instability or disequilibrium may be involved in the etiology of OI because postural stability is an essential element for static balance.

Methods
The study comprised 72 patients with ME/CFS (18 men and 54 women; mean age, 37±10 years), who underwent neurological examinations and the active 10-min standing test.

Results
Disequilibrium defined as instability on standing with their feet together and eyes shut, was detected in 23 (32%) patients while postural orthostatic tachycardia in 16 (22%). Compared with 49 patients without disequilibrium, patients with disequilibrium more prevalently failed to complete the 10-min standing test (74% vs. 4%, p<0.01) and body sway was significantly more prevalently observed during the test (100% vs. 12%, p<0.01).

The performance status score was significantly higher in patients with disequilibrium than those without it (median: 7 vs. 5, p<0.01), suggesting more severely restricted activity of daily living in the former. The prevalence of postural orthostatic tachycardia during the standing test was comparable between the patients with disequilibrium (23%) and those without it (22%, p=1.00). The 19 (26%) patients who failed to complete the 10-min standing test had disequilibrium more prevalently than those who completed it (89% vs. 11%, p<0.01).

Performance status score was significantly higher in patients who failed to complete it than those who completed it (median: 6 vs. 5, p<0.01), suggesting more severe restriction of activity of daily living in the former. Significantly higher rates of disequilibrium (89% vs. 11%, p<0.01), unstable standing on one leg (84% vs. 17%, p<0.01) as well as abnormal tandem gait (79% vs. 11%, p<0.01) were noted in patients who failed to complete it than those who completed it. Body sway during the standing test was significantly more prevalently observed in the patients who failed to complete it than those who completed it (89% vs. 23%, p<0.01).

The prevalence of postural orthostatic tachycardia during the standing test was comparable between the patients who failed to complete it and those who completed it (21% vs. 23%, p=1.00). Among the patients who failed to complete it 8 had the previous study records which revealed that 6 of them had completed it 6–24 months before when all the 6 patients had had no disequilibrium.

Conclusion
Disequilibrium should be recognized as an important cause of OI in patients with ME/CFS.

Posted in News | Tagged , , | Comments Off on Paradigm shift to disequilibrium in the genesis of orthostatic intolerance